Systematic Financial Management LP increased its holdings in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 2.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,745 shares of the company’s stock after acquiring an additional 620 shares during the quarter. Systematic Financial Management LP’s holdings in Medpace were worth $1,341,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Medpace by 82.2% in the 4th quarter. BlackRock Inc. now owns 4,158,359 shares of the company’s stock valued at $220,103,000 after buying an additional 1,876,296 shares during the period. Pendal Group Ltd increased its holdings in Medpace by 10,018.7% in the 4th quarter. Pendal Group Ltd now owns 1,593,387 shares of the company’s stock valued at $73,338,000 after buying an additional 1,577,640 shares during the period. Vanguard Group Inc. increased its holdings in Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after buying an additional 1,126,649 shares during the period. Bank of New York Mellon Corp increased its holdings in Medpace by 130.9% in the 4th quarter. Bank of New York Mellon Corp now owns 753,303 shares of the company’s stock valued at $39,872,000 after buying an additional 427,062 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in Medpace by 595.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 285,664 shares of the company’s stock valued at $15,121,000 after buying an additional 244,595 shares during the period. 83.50% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have commented on MEDP. BidaskClub lowered shares of Medpace from a “strong-buy” rating to a “buy” rating in a report on Friday, February 8th. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a report on Wednesday, April 10th. Wolfe Research began coverage on shares of Medpace in a report on Tuesday, April 2nd. They issued an “outperform” rating on the stock. Robert W. Baird raised their target price on shares of Medpace from $57.00 to $62.00 and gave the company a “neutral” rating in a report on Tuesday, April 30th. Finally, ValuEngine lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $59.25.
Shares of Medpace stock traded up $0.14 during midday trading on Friday, hitting $56.12. 4,213 shares of the company traded hands, compared to its average volume of 417,515. The firm has a market capitalization of $1.98 billion, a PE ratio of 21.71, a price-to-earnings-growth ratio of 1.68 and a beta of 1.51. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.09. Medpace Holdings Inc has a 12 month low of $40.73 and a 12 month high of $71.66.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $200.70 million for the quarter, compared to analyst estimates of $190.16 million. Medpace had a net margin of 10.49% and a return on equity of 17.16%. The firm’s revenue was up 23.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. As a group, research analysts anticipate that Medpace Holdings Inc will post 2.63 earnings per share for the current year.
In related news, CFO Jesse J. Geiger sold 12,000 shares of Medpace stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $58.20, for a total transaction of $698,400.00. Following the sale, the chief financial officer now directly owns 25,037 shares of the company’s stock, valued at approximately $1,457,153.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jesse J. Geiger sold 25,037 shares of Medpace stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $60.00, for a total transaction of $1,502,220.00. Following the sale, the chief financial officer now directly owns 25,037 shares in the company, valued at $1,502,220. The disclosure for this sale can be found here. Insiders have sold a total of 44,983 shares of company stock worth $2,661,091 over the last ninety days. 24.20% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by Macon Daily and is the sole property of of Macon Daily. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://macondaily.com/2019/05/17/systematic-financial-management-lp-acquires-620-shares-of-medpace-holdings-inc-medp.html.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Further Reading: How to calculate the annual rate of depreciation
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.